- Home
- KPTI vs TLSA Comparison
KPTI vs TLSA Comparison
Compare KPTI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- TLSA
- Stock Information
- Founded
- KPTI 2008
- TLSA 2013
- Country
- KPTI United States
- TLSA United Kingdom
- Employees
- KPTI N/A
- TLSA N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- TLSA Health Care
- Exchange
- KPTI Nasdaq
- TLSA Nasdaq
- Market Cap
- KPTI 81.1M
- TLSA 87.8M
- IPO Year
- KPTI 2013
- TLSA 2000
- Fundamental
- Price
- KPTI $0.62
- TLSA $0.79
- Analyst Decision
- KPTI Strong Buy
- TLSA
- Analyst Count
- KPTI 4
- TLSA 0
- Target Price
- KPTI $5.00
- TLSA N/A
- AVG Volume (30 Days)
- KPTI 751.1K
- TLSA 1.1M
- Earning Date
- KPTI 02-19-2025
- TLSA 02-25-2025
- Dividend Yield
- KPTI N/A
- TLSA N/A
- EPS Growth
- KPTI N/A
- TLSA N/A
- EPS
- KPTI N/A
- TLSA N/A
- Revenue
- KPTI $148,442,000.00
- TLSA N/A
- Revenue This Year
- KPTI $4.47
- TLSA N/A
- Revenue Next Year
- KPTI $7.35
- TLSA N/A
- P/E Ratio
- KPTI N/A
- TLSA N/A
- Revenue Growth
- KPTI 1.77
- TLSA N/A
- 52 Week Low
- KPTI $0.58
- TLSA $0.41
- 52 Week High
- KPTI $1.70
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- KPTI 43.29
- TLSA 56.56
- Support Level
- KPTI $0.58
- TLSA $0.65
- Resistance Level
- KPTI $0.67
- TLSA $0.70
- Average True Range (ATR)
- KPTI 0.05
- TLSA 0.05
- MACD
- KPTI -0.00
- TLSA 0.01
- Stochastic Oscillator
- KPTI 31.02
- TLSA 100.00
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.